Orbis Allan Gray Ltd Has $53.19 Million Stock Position in CRISPR Therapeutics AG $CRSP

Key Points

• Orbis Allan Gray Ltd has increased its stake in CRISPR Therapeutics AG by 5.9%, acquiring an additional 86,813 shares to reach a total of approximately 1,562,932 shares, valued at $53.2 million.
• Recent analyst reviews show mixed ratings for CRISPR Therapeutics, with nine analysts rating it as a Buy and one as a Sell, and a consensus price target of $71.60.
• Insider transactions included Director Simeon George acquiring a significant 989,812 shares for approximately $51.5 million, increasing their ownership by 133.69%.

Orbis Allan Gray Ltd increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 5.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,562,932 shares of the company's stock after buying an additional 86,813 shares during the period. Orbis Allan Gray Ltd owned 1.81% of CRISPR Therapeutics worth $53,187,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its holdings in CRISPR Therapeutics by 14.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 947,301 shares of the company's stock valued at $37,283,000 after purchasing an additional 122,695 shares during the period. Tower Research Capital LLC TRC boosted its holdings in CRISPR Therapeutics by 499.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,453 shares of the company's stock valued at $215,000 after purchasing an additional 4,544 shares during the period. Stifel Financial Corp boosted its holdings in CRISPR Therapeutics by 7.2% in the 4th quarter. Stifel Financial Corp now owns 43,128 shares of the company's stock valued at $1,698,000 after purchasing an additional 2,891 shares during the period. Hsbc Holdings PLC boosted its holdings in CRISPR Therapeutics by 16.1% in the 4th quarter. Hsbc Holdings PLC now owns 17,496 shares of the company's stock valued at $685,000 after purchasing an additional 2,426 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in CRISPR Therapeutics by 3.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,563 shares of the company's stock valued at $967,000 after purchasing an additional 800 shares during the period. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Price Performance

CRSP stock traded up $0.32 during trading on Wednesday, reaching $52.98. 1,636,234 shares of the company were exchanged, compared to its average volume of 2,559,581. The company has a 50-day moving average of $55.98 and a two-hundred day moving average of $45.42. The company has a market capitalization of $4.82 billion, a price-to-earnings ratio of -9.76 and a beta of 1.81. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The business had revenue of $0.89 million during the quarter, compared to analysts' expectations of $6.44 million. During the same period in the prior year, the company earned ($1.49) EPS. The firm's quarterly revenue was up 72.5% compared to the same quarter last year. On average, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director Simeon George purchased 989,812 shares of the firm's stock in a transaction on Wednesday, July 16th. The stock was purchased at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the transaction, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. The trade was a 133.69% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CRSP shares. HC Wainwright boosted their price objective on shares of CRISPR Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Thursday, August 7th. Royal Bank Of Canada boosted their target price on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a research report on Tuesday, August 5th. Zacks Research upgraded shares of CRISPR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 26th. The Goldman Sachs Group dropped their target price on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Finally, Piper Sandler restated an "overweight" rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $71.60.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.